Events8th International Electronic Conference on Medicinal Chemistry
Published
with-doi10.3390/ECMC2022-13198 (registering DOI)
This submission belongs to the session S4. Small molecules as drug candidates of the event 8th International Electronic Conference on Medicinal Chemistry
Published date
01 Nov, 2022
Academic Editor
author-avatarJennifer Wang
Citation
Anna Nikitjuka, Raivis Žalubovskis, Development of natural-like small inhibitors of selenoenzymes, in Proceedings of 8th International Electronic Conference on Medicinal Chemistry, 1 November–30 November 2022, MDPI: Basel, Switzerland, doi: 10.3390/ECMC2022-13198
Share
Email
Facebook
Twitter
LinkedIn

Development of natural-like small inhibitors of selenoenzymes

1. Latvian Institute of Organic Synthesis Aizkraukles 21, Riga, Latvia
Abstract

Physiological and pathological functions of thioredoxine reductase (TrxR) system in cellular processes have been extensively investigated. Available evidences approve that dysregulation of TrxR results in various human diseases, especially cancer.

An increasing number of TrxR inhibitors which are in clinical trials for the treatment of different types of cancers has been reported so far. However, construction of the specific inhibitors of TrxR over other related enzymes (e.g. glutathione reductase) remains a challenge.

One of our research direction, is synthesis of small, structurally diverse products to define a new and selective class of Trx inhibitors. Herein, we present a library of natural small compounds (including sanatmarine, coumarine and asparagusic acid derivatives) possessing a potential Michael acceptor moiety and disulfide bond, respectively. The preliminary biological activity results proved the obtained library to be specific inhibitors although the mechanism of action and stability is still under investigation.

Keywords
Selenoenzymes
Thioredoxin reductase
Michael acceptor
disulfide exchange
Poster
sciforum-065763.pdf
Search and analysis of information on porphyrin-like structures for the design of new compounds.
Interactionts between heterometallic bridged cis-or trans-Pt(II)-Zn(II)complexes and calf thymus DNA